Apogee Therapeutics, Inc. (APGE) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-10

Key Insights

Insider Michael Henderson, the CEO, sold a total of 20,000 shares of Apogee Therapeutics (APGE) on April 8, 2026, suggesting potential profit-taking.
The shares were sold at weighted average prices of $82.48 and $83.26, indicating the sales were executed at favorable market prices.
The sale reduced Henderson's direct beneficial ownership in the company from 1,135,187 shares to 1,132,987 shares, still maintaining a significant position.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-03

Insider Jane Henderson, the Chief Financial Officer, sold a total of 2,000 shares of Apogee Therapeutics, Inc. (APGE) on April 1, 2026 at weighted average prices of $84.46 and $85.46.
The sale was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating potential financial planning or diversification motives rather than a bearish sentiment.
Henderson still holds a substantial position of 177,371 shares, suggesting continued confidence in the company's long-term prospects.

Filed: 2026-04-03

Insider Carl Dambkowski, the Chief Medical Officer, exercised 4,125 stock options and sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) on April 1, 2026, generating over $465,000 in proceeds.
The stock sales were conducted pursuant to a 10b5-1 trading plan, indicating the transactions were pre-planned and not opportunistic.
Dambkowski continues to hold a significant direct ownership stake of 208,398 shares, representing his continued commitment to the company.

Filed: 2026-03-27

The reporting person, Jane Pritchett Henderson, is the Chief Financial Officer of Apogee Therapeutics, Inc. and has sold 2,000 shares of common stock on March 25, 2026.
The shares were sold at $85 per share, which is within the normal trading range for the stock.
The reporting person still beneficially owns 179,371 shares of Apogee Therapeutics' common stock, indicating they maintain a significant ownership position in the company.

Filed: 2026-01-22

Fairmount Funds Management LLC, a 10% owner of Apogee Therapeutics, Inc. (APGE), has sold 1.75 million shares of common stock at $76.30 per share.
Tomas Kiselak and Peter Harwin, directors of Apogee Therapeutics, each own 51,166 shares of common stock indirectly through Fairmount Healthcare Fund II LP.
Fairmount Healthcare Fund II LP owns 6,743,321 shares of non-voting common stock, which can be converted to common stock subject to a 9.99% ownership limit.

Filed: 2026-01-16

Insider Michael Henderson sold a significant number of Apogee Therapeutics shares (over 19,000 shares) on January 14, 2026 through a pre-planned 10b5-1 trading plan.
The sales were executed at high prices, with a weighted average price range of $78.64 to $83.79 per share, suggesting Henderson may have been locking in gains.
As CEO, Henderson's insider selling could potentially signal a lack of confidence in the company's near-term prospects, which investors may want to further investigate.

Other reports for Apogee Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.